Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
12/2013
12/27/2013WO2013189477A1 Emulsion for pharmaceutical use and method for the production thereof
12/27/2013WO2013189472A1 Emulsion for pharmaceutical use and method for the production thereof
12/27/2013WO2013189309A1 Microparticle comprising functional microrna/sirna and application thereof
12/27/2013WO2013189305A1 Valsartan-amlodipine compound solid preparation and preparation method therefor
12/27/2013WO2013189285A1 Application of piceatannol-3'-o-β-d-glucopyranoside in preparation of medicaments for improving microcirculation block
12/27/2013WO2013189266A1 Compound of camptothecin and preparation and use thereof
12/27/2013WO2013189241A1 Pyrimidine diamine derivative, preparation method therefor, and pharmaceutical uses thereof
12/27/2013WO2013189237A1 Andrographolide analogue and application of andrographolide analogue to treatment
12/27/2013WO2013189229A1 New use of 20(s)-protopanoxadiol
12/27/2013WO2013189219A1 Xanthine derivative
12/27/2013WO2013189121A1 Deuterated benzopyran compound and application thereof
12/27/2013WO2013188999A1 Application of inula lineariifolia lactone a in preparation of medicine for treating multiple sclerosis
12/27/2013WO2013188996A1 Application of inula lineariifolia lactone a in preparation of medicine for treating myocarditis
12/27/2013WO2013188928A1 Dosage regime for animal treatment
12/27/2013WO2013162298A8 Novel beta-alanine derivatives, pharmaceutically acceptable salts thereof, and pharmaceutical composition comprising same as active ingredient
12/27/2013WO2013157889A9 Use of a novel aminopyridine derivative to prevent or treat cancer
12/27/2013WO2013155338A3 Substituted benzamides and their uses
12/27/2013WO2013136346A3 Taste masking pharmaceutical orally dissolving strips of lornoxicam
12/27/2013WO2013134080A3 Improved method and compound for treatment of menopausal symptoms
12/27/2013WO2013128276A3 Tamper resistant immediate release formulations
12/27/2013WO2013124807A3 Oligonucleotides for modulating gene expression and uses thereof
12/27/2013WO2013121300A3 Methods for treating psoriasis and vascular inflammation
12/27/2013WO2013103874A8 Skin lightening compositions
12/27/2013WO2013091775A3 Use of cyclohexanol derivatives as antimicrobial active ingredients
12/27/2013WO2013018095A8 Compounds and compositions for use in augmentation of glucose uptake and insulin secretion
12/27/2013WO2013007361A9 Crystalline (1r,4r)-6'-fluoro-n,n-dimethyl-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine
12/27/2013WO2012170957A8 Retinoid-liposomes for enhancing modulation of hsp47 expression
12/27/2013WO2012162635A8 Metabotropic glutamate receptors 5 modulators and methods of use thereof
12/27/2013WO2012082672A3 Process and intermediates for preparing macrolactams
12/27/2013WO2012082337A3 Combination
12/27/2013WO2012078633A3 Methods of inhibiting metastasis from cancer
12/27/2013CA2877648A1 Polyvalent pneumococcal polysaccharide-protein conjugate composition
12/27/2013CA2877526A1 Complement pathway modulators and uses thereof
12/27/2013CA2877473A1 Imidazo bicyclic imminium compounds as antitumor agents
12/27/2013CA2877469A1 Substituted picolinamide kinase inhibitors
12/27/2013CA2877169A1 Pharmaceutical composition of moxifloxacin hydrochloride and preparation method
12/27/2013CA2877149A1 Substituted pyridine azolopyrimidine-5-(6h)-one compounds
12/27/2013CA2877146A1 Substituted thiophene- and furan-fused azolopyrimidine-5-(6h)-one compounds
12/27/2013CA2877122A1 Preparation, uses and solid forms of obeticholic acid
12/27/2013CA2877121A1 Sanitizer compositions comprising alcohol and an antimicrobial efficacy enhancer
12/27/2013CA2877097A1 Novel indanesulfamide derivative
12/27/2013CA2877089A1 Novel 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one and this1,2,3,4-tetrahydropyrimido{1,2-a}pyrimidin-6-one derivatives comprising a substituted morpholine, preparation thereof and pharmaceutical use thereof
12/27/2013CA2877034A1 Pyrimidinone derivatives as antimalarial agents
12/27/2013CA2877030A1 Multicomponent crystals comprising imatinib mesilate and selected co-crystal formers
12/27/2013CA2876982A1 Use of ferric citrate in the treatment of chronic kidney disease patients
12/27/2013CA2876979A1 Substituted bicyclic alkoxy pyrazole analogs as allosteric modulators of mglur5 receptors
12/27/2013CA2876977A1 Natural combination hormone replacement formulations and therapies
12/27/2013CA2876969A1 Substituted bicyclic alkoxy pyrazole analogs as allosteric modulators of mglur5 receptors
12/27/2013CA2876968A1 Soluble estradiol capsule for vaginal insertion
12/27/2013CA2876964A1 Progesterone formulations
12/27/2013CA2876957A1 Compounds with (1e, 6e)-1,7-bis-(3,4-dimethoxyphenyl)-4,4-disubstituted-hepta-1,6-diene-3,5-dione structural scaffold, their biological activity, and uses thereof
12/27/2013CA2876947A1 Transdermal hormone replacement therapies
12/27/2013CA2876945A1 1,2,4-triazine-6-carboxamide kinase inhibitors
12/27/2013CA2876939A1 Formulations for the preparation of immediate-release tablets for oral use containing low-dose mifepristone for the treatment of endometriosis, tablets thus obtained and their preparation process
12/27/2013CA2876935A1 Formulations for the preparation of immediate-release tablets for oral administration containing low-dose mifepristone, tablets thus obtained and their preparation process
12/27/2013CA2876926A1 Composition for treating or preventing vascular permeability-related disease containing imatinib or pharmaceutically acceptable salt thereof as active ingredient
12/27/2013CA2876909A1 Itraconazole compositions and dosage forms, and methods of using the same
12/27/2013CA2876907A1 Compounds from the fruits of acrocomia crispa and acrocomia aculata against inflammation and oxidative stress
12/27/2013CA2876584A1 Novel compound having ability to inhibit 11.beta.-hsdi enzyme or pharmaceutically acceptable salt thereof, method for producing same, and pharmaceutical composition containing same as active ingredient
12/27/2013CA2876357A1 Pharmaceutically active compounds
12/27/2013CA2876354A1 Transcription factor mediated programming towards megakaryocytes
12/27/2013CA2876321A1 Novel cabergoline derivatives
12/27/2013CA2876180A1 Oligonucleotide-based inhibitors comprising locked nucleic acid motif
12/27/2013CA2876001A1 Salt crystals
12/27/2013CA2875944A1 Novel anti-cancer compounds
12/27/2013CA2875916A1 Prodrug derivatives of (e)-n-methyl-n-((3-methylbenzofuran-2-yl)methyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamide
12/27/2013CA2875721A1 Deuterated benzopyran compound and application thereof
12/27/2013CA2875619A1 Aminotriazolopyridine for use in the treatment of inflammation, and pharmaceutical compositions thereof
12/27/2013CA2875589A1 Camsylate salt
12/27/2013CA2875588A1 Cyclohexane-1,2'-indene-1',2"-imidazole compounds and their use as bace inhibitors
12/27/2013CA2875497A1 Cyclohexane-1,2'-naphthalene-1',2"-imidazole compounds and their use as bace inhibitors
12/27/2013CA2875494A1 2h-imidazol-4-amine compounds and their use as bace inhibitors
12/27/2013CA2875455A1 Bendamustine derivatives and related compounds, and medical use thereof cancer therapy
12/27/2013CA2875454A1 Composition for patch preparation comprising drug, organic solvent, lipophilic mass base, and powder
12/27/2013CA2875389A1 1-[m-carboxamido(hetero)aryl-methyl]-heterocyclyl-carboxamide derivatives
12/27/2013CA2874950A1 Cycloalkyl ether compounds and their use as bace inhibitors
12/27/2013CA2874897A1 Method and composition for alleviating tumor symptoms
12/26/2013US20130345460 Ferric organic compounds, uses thereof and methods of making same
12/26/2013US20130345424 Compositions and uses thereof to ameliorate pain
12/26/2013US20130345417 Water soluble anionic bacteriochlorophyll derivatives and their uses
12/26/2013US20130345410 Novel antibacterial agents
12/26/2013US20130345314 Compositions and methods for treating a damaged cardiovascular element
12/26/2013US20130345313 Method for the treatment or prevention of lower urinary tract symptoms
12/26/2013US20130345310 Solid composition containing the ingredient rasagiline
12/26/2013US20130345309 Malic acid-enriched plant extract
12/26/2013US20130345308 Pharmaceutical and nutraceutical compositions of abscisic acid
12/26/2013US20130345306 Identification of c3 complement molecule at the site of injury to blood vessels in the retina of oxygen exposed animals
12/26/2013US20130345305 Powder emulsifier
12/26/2013US20130345303 Use of ferric citrate in the treatment of chronic kidney disease patients
12/26/2013US20130345301 Supplement composition and method of use
12/26/2013US20130345300 Small molecule modulators of the cold and menthol receptor trpm8
12/26/2013US20130345299 Composition comprising (-)-delta9-trans-tetrahydrocannabinol
12/26/2013US20130345297 Method for stabilizing amphiphilic block copolymer micelle composition containing poorly water-soluble drug
12/26/2013US20130345296 Compositions Comprising a Taxane for Coating Medical Devices
12/26/2013US20130345295 Targeted oncolytic adenovirus for treatment of human tumors, constrcution method and application thereof
12/26/2013US20130345286 Lipid formulated compositions and methods for inhibiting expression of eg5 and vegf genes
12/26/2013US20130345281 Conjugated 3-(indolyl)- and 3-(azaindolyl)-4-arylmaleimide compounds and their use in tumor treatment
12/26/2013US20130345280 Methods And Compositions Employing Bicifadine For Treating Disability Or Functional Impairment Associated With Acute Pain, Chronic Pain, Or Neuropathic Disorders
12/26/2013US20130345278 Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases
12/26/2013US20130345277 Modulators of GTPase and Use In Relevant Treatment
1 ... 437 438 439 440 441 442 443 444 445 446 447 448 449 450 451 452 453 454 455 456 457 ... 7860